drugset
drugset / Trial / NCT05045508

Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Photorefractive Keratectomy (PRK)

NCT05045508 ↗

Phase 3 Unknown 60 enrolled Brandon Baartman
RandomizedParallel-groupTriple-blindTreatment

Summary

Evaluate the safety and effectiveness of OC-01 (varenicline) nasal spray among subjects suffering from dry eye following photorefractive keratectomy (PRK)

Timeline

Start
2021-08-30
Primary completion
2022-08-30
Completion
2023-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Varenicline Small molecule 0.6 mg/ml Intranasal

Indications

dry eye syndrome